Lynq Sets July 15th Launch Date for Real-Time Interest-Bearing Settlement Network
The Lynq platform sets a new standard by delivering institutional clients instantaneous settlement capabilities while providing them with a mechanism to continually accrue interest. The growing industry support and continued momentum ahead of the July 15th launch reinforce the importance of building independent real-time settlement infrastructure for the benefit of the entire digital asset ecosystem.
'The digital asset community has been searching for a settlement solution that solves the challenges of market fragmentation and counterparty risk,' said Jerald David, CEO of Lynq. 'With Lynq, we are delivering a scalable and settlement utility that reduces friction, unlocks liquidity, and enables institutions to operate with full transparency.'
Lynq was developed by Arca Labs, Tassat, and tZERO with the goal of creating a settlement platform that meets the industry's demand for liquidity, scale, and security while maximizing capital efficiency for all network participants. Lynq's innovative architecture leverages tZERO's Broker-Dealer and Special Purpose Broker-Dealer licenses, Arca's expertise in asset management, and Tassat's proven, real-time blockchain settlement platform.
'Digital asset markets are entering a new structural phase that will be defined by real-time settlement, regulatory clarity, and institutional-grade infrastructure,' said Katryna Hanush, Director of Business Development and Partnerships at Wintermute. 'Lynq's launch is a pivotal step forward in that direction. It combines the ability to earn interest during settlement with the security and trust of established financial partners. This is the type of solution the industry needs, and Wintermute is proud to support it.'
Lynq's service partners include Avalanche, which provides the open-source Layer one blockchain network, and U.S. Bank, which serves as Lynq's qualified cash custodian.
To learn more about Lynq or to inquire about onboarding for the launch, please visit https://lynq.network.
About Lynq
Lynq is a broker-dealer-operated real-time settlement utility. Developed by Arca Labs, Tassat, and tZERO Group, and supported by a syndicate of leading digital asset and TradFiinstitutions, Lynq offers clients a scalable and inclusive settlement service on a proven end-to-end platform. Built 'by the industry, for the industry,' Lynq delivers interest and transparent proof of reserves within a bankruptcy-remote architecture that minimizes counterparty risk. Lynq's patent-pending 'Yield-in-Transit' technology enables users to maximize earned interest even during settlement operations, driving unprecedented capital efficiency. For more information, please visit https://lynq.network.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
9 hours ago
- Business Insider
Anthropic's cofounder says Meta's 'mega-offers' weren't enough to lure his team
Not even big offers from Meta were enough to tempt the team at Anthropic, said the AI startup's cofounder, Benjamin Mann. "It's not a hard choice," Mann said on an episode of "Lenny's Podcast" published Sunday. Other AI startups have seen key talent poached by mega paydays. "I think we've been maybe much less affected than many of the other companies in the space because people here are so mission-oriented," he said. "They get these offers and then they say, 'Well, of course I'm not going to leave because my best case scenario at Meta is that we make money, and my best case at Anthropic is we affect the future of humanity." Mann also said he doesn't blame anyone who takes those "mega offers." His comments come as tech giants like Meta and OpenAI engage in a fierce talent war, offering massive payouts to top AI researchers. "I'm pretty sure it's real," Mann said, referring to Meta's $100 million signing bonuses offered to AI engineers. "To pay individuals like $100 million over a four-year package, that's actually pretty cheap compared to the value created for the business," he said. "We're just in an unprecedented era of scale, and it's only going to get crazier." Mann also said that he and several other leaders left OpenAI in 2020 to start Anthropic because "safety wasn't the top priority there." A former researcher told Fortune last year that nearly half of OpenAI's safety team had exited. "People who are primarily focused on thinking about AGI safety and preparedness are being increasingly marginalized," said Daniel Kokotajlo, a former governance researcher. OpenAI said safety remains central to its mission. "Our responsibility to prepare for emerging security threats to users, customers, and global communities shapes everything we do," the company said on its website. Please help BI improve our Business, Tech, and Innovation coverage by sharing a bit about your role — it will help us tailor content that matters most to people like you. Continue By providing this information, you agree that Business Insider may use this data to improve your site experience and for targeted advertising. By continuing you agree that you accept the Terms of Service and Privacy Policy . The tech giant added that its API and ChatGPT products undergo routine third-party testing to "identify security weaknesses before they can be exploited by malicious actors." Mann, Anthropic, and OpenAI did not respond to a request for comment from Business Insider. Bidding war for top AI talen t Big Tech has always paid top dollar for elite talent, but the latest AI hiring frenzy has taken things to a whole new level, as BI previously reported. It started when Meta recruited Scale's CEO, Alexandr Wang, last month as part of a $14.3 billion deal to take a 49% stake in his company. Then, Sam Altman, the CEO of OpenAI, said Meta had tried to poach his best employees with $100 million signing bonuses. Meta pushed back, saying that the signing bonuses were not that generous. Meta's CEO, Mark Zuckerberg, announced last month that Wang would co-lead a new superintelligence unit with six top researchers from OpenAI. The bidding war for top AI talent has been likened to sports franchises competing for star athletes like Cristiano Ronaldo. Perplexity's CEO, Aravind Srinivas, said on a podcast published Thursday that Big Tech companies need to ensure that employees are motivated by mission as well as money. "You're encountering new kinds of challenges. You feel a lot of growth, you're learning new things. And you're getting richer, too, along the way. Why would you want to go just because you have some guaranteed payments?" he said. Srinivas also said that he was "surprised by the magnitude" of the salaries Zuckerberg is reportedly offering to top AI researchers, adding that it "seems like it's needed at this point for them." With the massive salaries, "failure is not an option" for Meta's new team, Srinivas said.
Yahoo
3 days ago
- Yahoo
Vonage's AWS Partnership Aims to Amp AI-Based Voice Communications
Vonage is dialing up voice-based artificial intelligence solutions. The cloud communications company announced this week that it would integrate Amazon Nova Sonic, powered by Amazon Web Services (AWS). Nova Sonic is a foundation model that uses human speech as input, then responds via an AI-powered voice agent. More from Sourcing Journal OpenAI Reportedly Works to Monetize ChatGPT's Shopping Function By Taking Commission Byte-Sized AI: Intel Spinout Creates Components for Physical AI; Bonx Grabs $8M for Manufacturing ERPs Chain Reaction: Asendia's Hendrick Kummeling on Why Strategic Flexibility is the Best Defense Against the Uncontrollable The idea is that, because Vonage's platform is set up to be able to use other developers' solutions, AWS can easily help the company implement Nova Sonic, which Vonage will use to allow clients to 'deploy real-time, natural-sounding AI voice agents' across several customer service channels: phone conversations, mobile apps and other services. Vonage anticipates that, in doing so, clients can provide a more human-like experience to their consumers, while enlisting AI-based tools to handle concerns that don't require immediate human intervention. That approach could help companies increase the efficiency of their human customer service operators, while also satisfying end consumers by providing quicker-turnaround answers to simple questions. Nova Sonic can answer consumers' questions quickly and expressively, AWS contends, noting that it tracks consumer sentiment throughout the duration of the call or chat to adjust its tone, pitch and approach accordingly based on the context of the interaction. Vonage's application programming interface (API) is set up such that Nova Sonic can be integrated directly, which helps reduce concerns over processing times and connection issues. Because of those considerations, Vonage and AWS said they have reason to believe the end solution will be scalable for businesses of varying sizes—and for several use cases. For instance, a major retailer might use the voice AI technology to assist a customer with a standard return, while a small-to-medium brand might prefer to use it to arrange in-store pickups with a consumer. Since the technology has access to a company's business insights in real time, it can adapt to meet the needs of many scenarios with natural language. That also means that complicated dial menus could become a thing of the past for adopters. Nova Sonic, paired with Vonage Voice API, can handle both inbound and outbound calls—that is to say that, while it can tackle customer queries, it can also call customers directly for pickup reminders, item confirmations and follow-up information from previous customer service calls as needed. Christophe Van de Weyer, president and head of business unit API at Vonage, said the companies' partnership will help Vonage customers deliver more practical AI-based consumer interactions. 'Vonage's latest collaboration with AWS enables organizations to transform how they engage with customers by adopting generative AI solutions that create added value for internal and external communications,' Van de Weyer said in a statement. 'This technology enables businesses to streamline the adoption of intelligent agents, accelerate the modernization of legacy voice systems, and provide a robust platform to deliver exceptional customer experiences with measurable improvements in satisfaction and operational efficiency.' Today, Nova Sonic is available in English, Spanish, French, Italian and German and offers both masculine and feminine intonations for voice agents assisting consumers. The companies' announcement did not address the capability for voice-based AI agents to speak with other AI agents in the future, but some companies have started planning for that. While what AWS and Vonage rolled out pertains mostly to front-end, consumer-facing operations, AI agents have shown more promise for back office processes, like tracking and rerouting shipments or alerting supply chain teams to factory delays and offering solutions. Flexport has actively started using AI agents to inquire with partners about the status of shipments, and CEO Ryan Petersen told Sourcing Journal this year that it's possible agents could begin speaking with one another—and consequently negotiating with one another on behalf of their respective companies. AWS and Vonage's partnership aims to create more accessible pathways for 'organizations to deploy intelligent voice agents at scale,' both companies said in the announcement. Once scaled for one use case—in this example, customer service—clients may eventually leverage voice-based AI agents for internal growth and business management. Sign in to access your portfolio
Yahoo
3 days ago
- Yahoo
ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing
Pharmaceutical companies and manufacturers, including MilliporeSigma (Burlington, US), Simtra BioPharma Solutions (Parsippany, US), Carbogen AMCIS (Bubendorf, Switzerland), and BioNTech (Mainz, Germany), have recently invested to meet growing demand for antibody drug conjugates (ADCs) as targeted cancer treatments. The global ADC market was $10bn in 2023 and is anticipated to exceed $58bn by 2030 (Figure 1). According to leading data and analytics company GlobalData, ADCs are expected to lead as the largest growing group of medicines in the innovation pipeline for 2025, as the industry has seen an increase in deals to develop and manufacture ADCs. Last week, MilliporeSigma and Simtra BioPharma Solutions announced a five-year partnership to offer ADC manufacturing services to pharmaceutical companies. MilliporeSigma will offer bioconjugation manufacturing at its ADC production facility in St. Louis, Missouri, US, while Simtra will offer drug product formulation and fill-finish services. Both companies will cover the analytical work for ADC production. MilliporeSigma has a history of prioritising ADC production - the company invested $76m into its St. Louis facility in 2024, in addition to the $65m spent five years ago to build its ADC active pharmaceutical ingredient (API) site in Madison, Wisconsin, US. Last year, Simtra announced a $14m investment to expand its ADC conjugation and purification capabilities. Earlier this month, Carbogen AMCIS, an API manufacturer, along with an unnamed Japanese partner, shared that they would invest $31m to prepare two facilities in Switzerland for the commercial production of linkers by the first quarter (Q1) and Q3 2027. Another Swiss contract development and manufacturing organisation (CDMO), Lonza (Basel, Switzerland), also revealed plans to increase its ADC production capabilities last year, with the addition of two manufacturing suites to its Visp, Switzerland, site. Last month, BioNTech announced that it was preparing to file for US Food and Drug Administration (FDA) approval in second-line endometrial cancer later this year for its next-gen human epidermal growth factor receptor 2-targeted ADC, BNT323. Currently, the company is 'reliant on a China-based CDMO' to supply BNT323. However, the company shared plans to diversify its supply chain and decrease dependence on its Chinese partner by adding multiple BNT323 'supply nodes'. With impending tariffs on pharmaceuticals under the current government, there has been a rise in deals and investment to grow US manufacturing operations. Combined with the surge of ADC demand for oncology indications, clinical and commercial manufacturing contracts for ADCs are anticipated to increase. Although only 6% of the current ADC landscape is made up of marketed drugs, the ADC addressable market is expected to grow over the next decade, with 268 drugs currently in clinical stages of development (Figure 2). "ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
